Monthly Update30 Jun 2025, 08:49 am
Biocon Biologics Supplies Over 100 Million Cartridges of Insulin to Malaysian Health Ministry
AI Summary
Biocon Biologics Ltd., a global biosimilars company, announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has supplied over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health. This achievement marks a significant milestone in Biocon Biologics’ commitment to advancing diabetes care and ensuring affordable access to insulin in Malaysia, serving over 345,000 patients since 2016.
Key Highlights
- Biocon Biologics surpasses the milestone of supplying 100 million cartridges of rh-insulin to Malaysia’s Ministry of Health.
- The company has served over 345,000 diabetes patients in Malaysia since 2016.
- Biocon Biologics’ public-private partnership with the Malaysian government exemplifies a successful model for building a resilient biotech ecosystem.
- The company has established a Center of Excellence for insulins at its state-of-the-art manufacturing facility in Johor, Malaysia.
- Biocon Biologics is committed to serving ‘1 in 5’ insulin-dependent people worldwide and has provided 9.2 billion doses of rh-Insulin and Insulin Glargine cumulatively to patients across the globe.